非布司他

**非布司他**
系统（IUPAC）命名名称
	2-(3-cyano-4-isobutoxyphenyl)-4-methyl-; 1,3-thiazole-5-carboxylic acid
临床数据
商品名	Uloric, Adenuric[1]
Drugs.com	Monograph
MedlinePlus	a609020
医疗法规	EU EMA: yes; US DailyMed: Febuxostat;
妊娠分级	AU: B1 [2]; US: N (当前暂无分类) [2];
给药途径	口服
合法狀態
合法状态	US: 处方药（℞-only） ; EU: Rx-only ;
药代动力学数据
生物利用度	≥84% absorbed
蛋白结合度	99.2%至albumin
代谢	通過CYP1A1, CYP1A2, CYP2C8, CYP2C9, UGT1A1, UGT1A8, UGT1A9[3]
生物半衰期	~5–8 小時
排泄	Urine (~49%, mostly as metabolites, 3% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug)
识别
CAS注册号	144060-53-7
ATC代码	M04AA03
PubChem	CID 134018
IUPHAR/BPS	6817
DrugBank	DB04854
ChemSpider	118173
UNII	101V0R1N2E
KEGG	D01206
ChEBI	CHEBI:31596
ChEMBL	CHEMBL1164729
化学
化学式	C16H16N2O3S
摩尔质量	316.38 g·mol−1
	SMILES N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C;
	InChI InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) ; Key:BQSJTQLCZDPROO-UHFFFAOYSA-N ;

非布司他（Febuxostat）是一种用于治疗痛风的药物，而藥品所針對的痛風基本因尿酸水平过高而引起[4]。該藥物通過抑制黄嘌呤氧化酶，从而减少体内尿酸的产生。該藥的給藥途徑為口服。該藥常见的副作用包括肝脏出現问题、恶心、关节痛和皮疹[4]等症狀。妊娠或哺乳期婦女不建议服用該藥物[5][6]。

非布司他于2008年和2009年分别在欧盟和美国被批准用于医疗用途[7][4]。2019年，還藥的仿制藥被監管部門批准，2020年起正式上市[8] [9]。

参考文献

Drugs.com Drugs.com international names for febuxostat Page accessed June 25, 2015
. Drugs.com. 22 February 2019 [17 May 2020].
(PDF). European Medicines Agency. 2019-08-06.
. Drugs.com. American Society of Health-System Pharmacists. [26 February 2019] （英语）.
76. Pharmaceutical Press. 2018: 1087. ISBN 9780857113382.
. FDA. 21 February 2019 [26 February 2019] （英语）.
. European Medicines Agency - Commission. 17 September 2018 [26 February 2019] （英语）.
. Drugs.com. [1 August 2019] （英语）.
. [15 April 2020].

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[drugnames-1] Drugs.com Drugs.com international names for febuxostat Page accessed June 25, 2015

[Drugs.com_pregnancy-2] . Drugs.com. 22 February 2019 [17 May 2020].

[EMA-3] (PDF). European Medicines Agency. 2019-08-06.

[AHFS2019-4] . Drugs.com. American Society of Health-System Pharmacists. [26 February 2019] （英语）.

[BNF76-5] 76. Pharmaceutical Press. 2018: 1087. ISBN 9780857113382.

[FDA2019-6] . FDA. 21 February 2019 [26 February 2019] （英语）.

[7] . European Medicines Agency - Commission. 17 September 2018 [26 February 2019] （英语）.

[8] . Drugs.com. [1 August 2019] （英语）.

[9] . [15 April 2020].